-
Mashup Score: 1
Watch this videoclip from the Gopi Gnanasegaran presentation at #IUCS23 titled “Theragnostics in mPCa: Diagnosis and Treatment”
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 16Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts - 7 month(s) ago
Current Oncology Reports – To discuss recent advances in the treatment of advanced urothelial carcinoma (UC) and how best to incorporate new therapies into clinical practice. There have been…
Source: link.springer.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3Urology Cancer Summit - 7 month(s) ago
The First International Urology Cancer Summit is a free and independent educational opportunity open to everyone involved in caring for patients with urologic cancers.
Source: urologycancersummit.orgCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
Watch this videoclip from the Gopi Gnanasegaran presentation at #IUCS23 titled “Theragnostics in mPCa: Diagnosis and Treatment”
Source: www.youtube.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0GHA to host cancer conference later this month - 7 month(s) ago
The GHA will be hosting a cancer conference at the Sunborn Hotel on Thursday, October 26, between 7pm to 9pm. The conference aims to showcase the diverse efforts and accomplishments of the GHA clinical team in both the Palliative Care and Cancer D…
Source: www.chronicle.giCategories: Latest Headlines, Oncologists2Tweet-
Very much looking forward to being at GHA with David Ballesteros @tsellab to discuss The Evolution of Cancer Treatment: From Past to Present and Beyond Thanks for the opportunity to reflect on the rmeaningful achievements in #oncology and #canceresearch https://t.co/glOB70D8Dd https://t.co/RWZwDXZ4zW
-
-
Mashup Score: 115Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial - 7 month(s) ago
Nature Medicine – In a phase 2 trial, the combination of gemcitabine, cisplatin and anti-PD-1 led to a clinical complete response in 43% of patients with muscle-invasive bladder cancer, which…
Source: www.nature.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 8
PURPOSE ARTO (ClinicalTrials.gov identifier: NCT03449719) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS All patients were affected by oligometastatic CRPC as defined as three or less nonvisceral metastatic lesions. Patients were randomly assigned 1:1 to receive either AAP alone (control arm) or AAP with concomitant SBRT to all the sites of disease (experimental arm). Primary end point was the rate of biochemical response (BR), defined as a prostate-specific antigen (PSA) decrease ≥50% from baseline measured at 6 months from treatment start. Complete BR (CBR), defined as PSA < 0.2 ng/mL at 6 months from treatment, and progression-free survival (PFS) were secondary end points. RESULTS One hundred and fifty-seven patients were enrolled between January 2019 and September
Source: ascopubs.orgCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 53The OncoAlert Newsletter is NOW OUT Click to Register - 8 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 26The OncoAlert Newsletter is NOW OUT Click to Register - 9 month(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 20Association of Immunotherapy Duration With Overall Survival in Advanced Non–Small Cell Lung Cancer - 9 month(s) ago
This cohort study of advanced non–small cell lung cancer patients assesses practice patterns surrounding immunotherapy discontinuation at 2 years and evaluates the association of duration of therapy with overall survival.
Source: jamanetwork.comCategories: Latest Headlines, Oncologists2Tweet-
Still many believe in indefinite duration of #immunotherapy for #lungcancer over fixed 2 years. Actually, 2 years are enough by this large US #oncology database analysis. Notably, re-challenge not as effective as expected. https://t.co/jjiuhFiBns @JAMAOnc @OncoAlert @OncoViews https://t.co/C2eCXm9pk9
-
RT @urologysummit: Listen to what Gopi Gnanasegaran told at #IUCS23 about diagnostic #PSMA PET https://t.co/kgoIIHGu4m @gbanna74 @ravikanes…